Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech IncfiledCriticalJanssen Biotech Inc
Publication of AR122819A1publicationCriticalpatent/AR122819A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Los métodos para tratar a un sujeto humano que tiene una enfermedad asociada con el factor regulador de interferón 5 (IRF5) comprenden administrar al sujeto un oligómero antisentido a un ácido nucleico de IRF 5.Methods of treating a human subject having an interferon regulatory factor 5 (IRF5) associated disease comprise administering to the subject an antisense oligomer to an IRF 5 nucleic acid.
ARP210101838A2020-07-012021-06-30
METHODS OF SAFE ADMINISTRATION OF AN IRF5 ANTISENSE OLIGONUCLEOTIDE
AR122819A1
(en)